PHIBRO ANIMAL HEALTH CORP (PAHC) Stock
5 of the hedge funds AlphaScala tracks reported PAHC in 13F filings for the quarter ended Jun 30, 2026; the largest reported position is Millennium Management's at $29.41M.
Which hedge funds own PAHC?
From 13F filings| Fund | Shares Held | Position Value | Change vs prior Q |
|---|---|---|---|
| Millennium Management Israel Englander | 937K | $29.41M | +1578% |
| Renaissance Technologies Jim Simons (founder) | 481K | $15.09M | -17% |
| D.E. Shaw David Shaw | 27K | $856.1K | +222% |
| Citadel Ken Griffin | 15K | $467.5K | NEW |
| Marshall Wace | 11K | $340.2K | +59% |
13F holdings as of Jun 30, 2026
Explore all tracked funds →PAHC price chart
Powered by TradingViewWhat does PHIBRO ANIMAL HEALTH CORP do?
Phibro Animal Health Corporation is a pharmaceutical company that focuses on the development, manufacturing, and marketing of a wide range of animal health and mineral nutrition solutions. Primarily, the company serves the livestock and poultry sectors by providing medications and vaccines that enhance the health and productivity of animals. Phibro's extensive product portfolio includes antimicrobials, vaccines, mineral premixes, and specialty products developed to support the animal agriculture industry. The company plays a significant role in improving animal welfare as well as animal-derived food safety, thus contributing directly to the agricultural supply chain. Established in 1946 and headquartered in Teaneck, New Jersey, Phibro operates globally, catering to the needs of veterinarians, farmers, and feed producers across diverse markets. Its products are pivotal in addressing challenges such as outbreaks of diseases among livestock, thereby helping to ensure the profitability and sustainability of animal farming operations worldwide.